Otezla rejected by NICE
The National Institute for Health and Care Excellence has issued final guidance not recommending Otezla (apremilast; Celgene) for the treatment of moderate to severe plaque psoriasis in the NHS in England and Wales. This is because the medicine is not considered to be cost-effective.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069474
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com